Influence of Sex and Age on Site of Onset, Morphology, and Site of Metastasis in Colorectal Cancer: A Population-Based Study on Data from Four Italian Cancer Registries.

age cancer registry colorectal cancer metastasis population-based relative survival sex

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Jan 2023
Historique:
received: 16 11 2022
revised: 10 01 2023
accepted: 27 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 12 2 2023
Statut: epublish

Résumé

The prognosis of colorectal cancer is affected by factors such as site of origin, tumor morphology, and metastasis at diagnosis, but also age and sex seem to play a role. This study aimed to investigate within the Italian population how sex and age interact in influencing certain aspects of the disease and how they affect patient survival, particularly in the metastatic cohort. Data from four cancer registries were collected, and patients were classified by sex and age (<50, 50-69, and >69 years). Two separate analyses were conducted: one for patients having right or left colon cancer with adenocarcinoma or mucinous morphology, and one for patients having metastases at diagnosis. Women showed significant differences in right colon cases from the youngest to oldest age group (36% vs. 45% vs. 60%). Men <50 years had a significantly higher mucinous carcinoma percentage than their female counterparts (22% vs. 11%), while in the oldest age group women had the highest percentage (15% vs. 11%). The metastatic pattern differed between men and women and by age. The three-year relative survival in the <50 age group was better for women than men, but this survival advantage was reversed in the oldest group. In conclusion, sex and age are factors that influence the biological and clinical characteristics of colorectal cancer, affecting the metastatic pattern as well as patient survival.

Identifiants

pubmed: 36765761
pii: cancers15030803
doi: 10.3390/cancers15030803
pmc: PMC9913256
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Med. 2021 Dec;10(23):8708-8719
pubmed: 34697912
Front Oncol. 2020 Dec 09;10:607909
pubmed: 33363037
Oncotarget. 2015 Nov 17;6(36):38658-66
pubmed: 26484417
Eur J Cancer. 2012 Mar;48(4):501-9
pubmed: 22226571
Ann Surg Oncol. 2020 May;27(5):1580-1588
pubmed: 31792717
Abdom Radiol (NY). 2022 Feb;47(2):530-537
pubmed: 34894278
Cancer Treat Rev. 2015 Sep;41(8):671-9
pubmed: 26145760
Nat Rev Cancer. 2016 May;16(5):330-9
pubmed: 27079803
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34209162
J Gastroenterol Hepatol. 2008 Mar;23(3):418-23
pubmed: 17532785
BMC Cancer. 2018 Jan 15;18(1):78
pubmed: 29334918
Clin Cancer Res. 2009 Oct 15;15(20):6391-7
pubmed: 19789331
Mol Biol Rep. 2020 May;47(5):4087-4091
pubmed: 32246248
Digestion. 2018;98(3):143-152
pubmed: 29870979
PLoS One. 2013 Jul 05;8(7):e68077
pubmed: 23861851
Clin Cancer Res. 2013 Nov 1;19(21):5842-8
pubmed: 23965904
Ann Surg. 2018 Mar;267(3):514-520
pubmed: 28002060
Clin Colorectal Cancer. 2019 Mar;18(1):e104-e116
pubmed: 30448100
Sci Rep. 2021 Sep 7;11(1):17785
pubmed: 34493755
Am J Clin Oncol. 2011 Dec;34(6):573-80
pubmed: 21217399
Cancer Lett. 2016 Mar 1;372(1):48-56
pubmed: 26708506
Am J Surg. 2004 Mar;187(3):343-8
pubmed: 15006562
Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):342-351
pubmed: 34853022
Am J Surg. 2020 Aug;220(2):408-414
pubmed: 31864521
Ann Oncol. 2014 Mar;25(3):651-657
pubmed: 24504447
BMC Cancer. 2018 Sep 20;18(1):906
pubmed: 30236083
Eur J Surg Oncol. 2015 Mar;41(3):300-8
pubmed: 25468456
Sci Rep. 2015 May 27;5:10645
pubmed: 26013439
J Clin Oncol. 2011 Nov 20;29(33):4401-9
pubmed: 21969498
Am J Clin Oncol. 2021 Jul 1;44(7):315-324
pubmed: 33899807
Int J Cancer. 2017 Nov 15;141(10):1942-1949
pubmed: 28599355
J Zhejiang Univ Sci B. 2009 Mar;10(3):219-29
pubmed: 19283877

Auteurs

Viviana Perotti (V)

Cancer Registry Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Sabrina Fabiano (S)

Cancer Registry Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Paolo Contiero (P)

Environmental Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Maria Michiara (M)

Department of Medicine and Surgery, University of Parma, Medical Oncology, Cancer Registry, University Hospital of Parma, 43100 Parma, Italy.

Antonio Musolino (A)

Department of Medicine and Surgery, University of Parma, Medical Oncology, Cancer Registry, University Hospital of Parma, 43100 Parma, Italy.

Lorenza Boschetti (L)

Epidemiology Unit, Health Protection Agency of Pavia (ATS Pavia), 27100 Pavia, Italy.

Giuseppe Cascone (G)

Ragusa Cancer Registry, Department of Prevention, Ragusa Health Authority, 97100 Ragusa, Italy.

Maurizio Castelli (M)

Cancer Registry, Aosta Valley Health Authorities Department of Public Health, 11100 Aosta, Italy.

Giovanna Tagliabue (G)

Cancer Registry Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Classifications MeSH